In conclusion, this study served as further proof of concept that a chemotherapeutic agent-siRNA combination therapy could yield a superior response compared to that of single-agent treatments and highlights the combination treatment of Dox and Mcl-1 siRNA as an attractive candidate for novel breast cancer therapy. This evidence concerns the gene MCL1 and breast cancer.